Mahesh M
★    

India,
2016-08-18 14:50
(2779 d 17:32 ago)

Posting: # 16560
Views: 6,794
 

 multiple dosage study [Regulatives / Guidelines]

Dear All,

For EMA submission of prolonged release dosage form is it possible to Waiver for multiple dosage study on the basis of evidence of “lack of accumulation (by SPC, PAR or literature) and the provide partial AUC for both fasting and fed two way study as supportive?


Regards
VStus
★    

Poland,
2016-08-24 23:37
(2773 d 08:46 ago)

@ Mahesh M
Posting: # 16572
Views: 5,647
 

 multiple dosage study

Hi Mahesh,

❝ “lack of accumulation" (by SPC, PAR or literature) and the provide partial AUC for both fasting and fed two way study as supportive data.


On my opinion, it's clearly stated that SPC, PAR or literature is not sufficient as both Test and Reference product's data are required:

6.1.1.2. Multiple dose studies
A multiple dose study is needed unless a single dose study has been performed with the highest strength which has demonstrated that the mean AUC(0-tau) after the first dose covers more than 90% of mean AUC(0-∞) for both test and reference, and consequently a low extent of accumulation is expected.


Best regards,
VStus
Mahesh M
★    

India,
2016-08-25 11:36
(2772 d 20:46 ago)

@ VStus
Posting: # 16573
Views: 5,833
 

 multiple dosage study

Hi VStus,

Thank you so much for your response.

Can we use partial AUC (labeled dose interval) from both fasting and fed two way study instead of AUC(0-tau)?

Please find below link for recently published PAR of metformin.

http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con713246.pdf

In this PAR Applicant performed three BE study on 500 mg strength:
Fasting 500 mg two way
Fed 500 mg two way
Multiple 500 mg fed
Applicant failed to demonstrate BE on multiple dose fed BE study but got approval on the basis of evidence of “lack of accumulation and the provide partial AUC for both fasting and fed two way study as supportive.

Regards
VStus
★    

Poland,
2016-08-25 20:34
(2772 d 11:49 ago)

@ Mahesh M
Posting: # 16576
Views: 5,809
 

 multiple dosage study

Hi, Manesh!

❝ Can we use partial AUC (labeled dose interval) from both fasting and fed two way study instead of AUC(0-tau)?


I can only cite same section of the Guideline once more again... Why not if there is no accumulation and partialAUCs will demonstrate BE. What if these parameters will be highly variable?

http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con713246.pdf


Thank you for the reference!

Regards, VStus
BE-proff
●    

2016-08-26 12:45
(2771 d 19:37 ago)

@ VStus
Posting: # 16580
Views: 5,896
 

 multiple dosage study

Hi VStus,

Unless I am mistaken, to comply with the statement you have cited we need to conduct steady state study anyway.

Otherwise, how to get AUC0-tau? ;-)
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2016-08-26 13:08
(2771 d 19:15 ago)

@ BE-proff
Posting: # 16581
Views: 5,632
 

 τ in SD = intended dosage interval

Hi BE-proff,

❝ Unless I am mistaken,


You are. ;-)

❝ … to comply with the statement you have cited we need to conduct steady state study anyway. Otherwise, how to get AUC0-tau? ;-)


The MR GL again, this time with the important part in red:

A multiple dose study is needed unless a single dose study has been performed with the highest strength which has demonstrated that the mean AUC(0-τ) after the first dose covers more than 90% of mean AUC(0-∞) for both test and reference, and consequently a low extent of accumulation is expected.


Here τ is the intended dosage interval for the labeled posology. Say you want to dose b.i.d. (τ=12). In the SD study you will sample long enough to get a reliable estimate of λz (for the calculation of AUC0-∞). Now you have to show that AUC0–12 covers more than 90% of AUC0-∞ in order to waive the MD study.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Mahesh M
★    

India,
2016-08-26 16:17
(2771 d 16:06 ago)

@ Helmut
Posting: # 16586
Views: 5,554
 

 multiple dosage study

Hi Helmut,

Thank you so much for your response its really help us a lot.

Regards
mittyri
★★  

Russia,
2016-08-26 19:43
(2771 d 12:40 ago)

@ Helmut
Posting: # 16593
Views: 5,621
 

 Some questions from EGA regarding MR Guideline

Hi Helmut,

I've found a presentation released by European Generic and Biosimilar Medicines Association.
I suppose you are familiar with it.

They are asking very interesting questions, regarding waiving MD too. Could you please comment their questions?
At least this one:

Accumulation, i.e. AUC0-τ steady state / AUC0-τ after first administration is

  • 11% with the current 90% criterion
  • 25% with an 80% criterion

For linearity assessment, a ±25% difference in AUC is acceptable.

We would like to get clarification regarding the rationale behind the 90% criterion.


Kind regards,
Mittyri
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2016-08-26 21:42
(2771 d 10:41 ago)

@ mittyri
Posting: # 16594
Views: 5,752
 

 Quod licet Iovi, non licet bovi

Hi mittyri,

❝ I've found a presentation released by European Generic and Biosimilar Medicines Association.

❝ I suppose you are familiar with it.


Yes, I’ve been there.

The answer of the panelists (members of the PKWP) essentially was „We want it that way”. When reminded that MD studies are generally not required by the FDA at all (‼), 20% extrapolated AUC is the limit in Canada for many years, and we have no evidence of any problems on the other side of the pond one panelist replied „We could have required 5% as well”

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
106 visitors (0 registered, 106 guests [including 4 identified bots]).
Forum time: 07:23 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5